As representatively shown with the B16-sMICB tumor model, in response to monotherapy with B10G5 or ALT-803, not only the number of NK cells (CD3−NK1.1+) but also the level of NKG2D expression, measured by the percentage of NKG2D+ NK cells and the mean fluorescence intensity (MFI) of the NKG2D expression on NKG2D+ NK cells, in the spleen and tumor-draining inguinal lymph nodes (dLN) was markedly increased in comparison to the control treatment group (Figure 2a–2c and Supplementary Figure S1a). Here, KLRK1 is linked to neoplasm.